However, though half of PDAC patients will exhibit genetic loss of TGFβ/SMAD signaling in the tumor epithelium, the corresponding alterations in the pancreatic tumor immune microenvironment have yet to be described. The gene discussed is TGFB1; the disease is neoplasm.